Delving into the Latest Updates on Cyclosporine (Huons) with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide

Synonyms

Ciclosporin (Huons), Clacier

+ [2]

Target

CaN

Action

inhibitors

Mechanism

CaN inhibitors(Calcineurin inhibitors)

Therapeutic Areas

Eye Diseases

Active Indication

Xerophthalmia

Inactive Indication-

Originator Organization

Huons Co., Ltd.

Active Organization

Huons Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

South Korea (26 Nov 2018),

Xerophthalmia

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC62H111N11O12

InChIKeyPMATZTZNYRCHOR-CGLBZJNRSA-N

CAS Registry59865-13-3

Ocular Graft Versus Host Disease (OGVHD) is a serious potential complication of allogeneic bone marrow transplants. The usual treatment is topical cyclosporine but when the treatment is initiated the damage to the lacrimal glands has already taken place.
The present study aims to prevent OGVHD in reduced-intensity allogeneic hematopoietic transplants by using topical cyclosporine immediately after the engraftment has been achieved

Start Date01 May 2014

Sponsor / Collaborator

Hospital Universitario. Dr. José Eleuterio González

100 Clinical Results associated with Cyclosporine (Huons)

Login to view more data

100 Translational Medicine associated with Cyclosporine (Huons)

Login to view more data

100 Patents (Medical) associated with Cyclosporine (Huons)

Login to view more data

31,670

Literatures (Medical) associated with Cyclosporine (Huons)

01 Feb 2025·Food Chemistry

Taste characterization and molecular docking study of novel umami flavor peptides in Yanjin black bone Chicken meat

Article

Author: Zhao, Ping ; Yang, Chaohui ; Ge, Changrong ; Ge, Xuehai ; Xiao, Zhichao ; Liang, Shuangmin

Five polypeptides with a potential umami taste were isolated and purified from Yanjin black bone chicken. However, the flavor characteristics and umami mechanism have not been clarified. The umami properties of these five peptides were investigated in this work using a range of analytical techniques, computer simulation, and sensory evaluation. HE-10 and TP-7 exhibited the strongest umami flavors. Furthermore, dose-response experiments showed that the umami peptides enhanced umami by generating peptide mineral chelates. Environmental scanning electron microscopy (ESEM) microstructural analyses supported this finding. The molecular docking results indicated that the five polypeptides bind to four critical amino acid residues, namely Glu217, Glu148, Asp216, and His145, of the T1R1/T1R3 receptor. The binding occurred through van der Waals, electrostatic interactions, hydrogen bonding, and hydrophobic interactions. The main surface forces implicated include aromatic interactions, hydrogen bonding, hydrophilicity, and solvent accessibility.

31 Dec 2024·Virulence

Immunosuppressants exert antiviral effects against influenza A(H1N1)pdm09 virus via inhibition of nucleic acid synthesis, mRNA splicing, and protein stability

Article

Author: Zhang, Jiayou ; Yang, Xuanye ; Duan, Kai ; Wang, Xin ; Yang, Xiao-Ming ; Pu, Feiyang ; Nian, Xuanxuan ; Ma, Xiao-Xia ; Ma, Zhongren ; Feng, Xili

Influenza A virus (IAV) poses a threat to patients receiving immunosuppressive medications since they are more susceptible to infection with severe symptoms, and even death. Understanding the direct effects of immunosuppressants on IAV infection is critical for optimizing immunosuppression in these patients who are infected or at risk of influenza virus infection. We profiled the effects of 10 immunosuppressants, explored the antiviral mechanisms of immunosuppressants, and demonstrated the combined effects of immunosuppressants with the antiviral drug oseltamivir in IAV-infected cell models. We found that mycophenolic acid (MPA) strongly inhibits viral RNA replication via depleting cellular guanosine pool. Treatment with 6-Thioguanine (6-TG) promoted viral protein degradation through a proteasomal pathway. Filgotinib blocked mRNA splicing of matrix protein 2, resulting in decreased viral particle assembly. Furthermore, combined treatment with immunosuppressants and oseltamivir inhibits IAV viral particle production in an additive or synergic manner. Our results suggest that MPA, 6-TG, and filgotinib could be the preferential choices for patients who must take immunosuppressants but are at risk of influenza virus infection.

31 Dec 2024·Hematology

High- vs regular-dose recombinant human thrombopoietin plus cyclosporine A in patients with newly diagnosed non-severe aplastic anemia: a retrospective cohort study

Article

Author: Yang, Yuan ; Han, Bing ; Chen, Miao ; Yang, Chen ; Hu, Qinglin

BACKGROUNDCyclosporine A (CsA) and regular doses of recombinant human thrombopoietin (rhTPO) can accelerate platelet recovery in patients with non-severe aplastic anemia (NSAA). However, it is unclear whether CsA plus rhTPO at a higher dose can further increase the efficacy.METHODSData from patients with newly diagnosed NSAA, who had been treated with CsA in combination with different doses of rhTPO between February 2021 and August 2021 at Peking Union Medical College Hospital, were reviewed. All the enrolled patients had been treated with CsA at 3-5 mg/(kg/d), and patients were further classified into high-dose (with rhTPO 30000U qd × 14 days for 2 months) group or regular-dose (with rhTPO 15000U qd × 7days for 3 months) group. The treatment response and therapy-related adverse events were compared.RESULTS36 patients including 16 (44.4%) in the high-dose and 20 (55.6%) in the regular-dose group were enrolled. The baseline characteristics were compatible between the two groups. The platelet counts were significantly higher at 1/3/6 months in the high-dose group (p = 0.028, 0.0063 and p = 0.040, respectively). The high-dose group had a significantly shorter time to platelet transfusion independence ([1 (0.5-6) months vs 2.5 (1-12) months, p = 0.040]). There was no significant difference in overall response and complete response rate between the two groups at 1/3/6/12 months (p > 0.05). Treatment-related morbidities were similar between the two groups (p > 0.05).CONCLUSIONSAdding a higher dose of rhTPO can further accelerate platelet recovery and platelet transfusion independence in patients with newly diagnosed NSAA.

100 Deals associated with Cyclosporine (Huons)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB00091

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Xerophthalmia	South Korea	Huons Co., Ltd.	26 Nov 2018

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Dry Eye Syndromes	Discovery	-	Huons Co., Ltd.	01 May 2013

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00987480 (CTgov)	Phase 2	Acute Myeloid Leukemia \| Leukemia \| acute leukemia \| Anemia, Refractory \| Myelodysplastic Syndromes \| Fanconi Anemia	45	CliniMACS device+fludarabine+Busulfan+cyclosporine.+cyclophosphamide	woadpjcpkj(gthgfvoyde) = wplpympfnr sapdnmrxuk (jeoqsaozyd, dvoeymdsqy - hhijuddedb) View more	-	10 Jul 2018
NCT00974142 (CTgov)	Phase 1/2	Pulmonary Disease, Chronic Obstructive	43	Cyclosporine (Cyclosporine)	nfzsqtqril(oyhvosrggj) = eowljwfjyz nvwxhlnrzi (uzxipreshi, dmvrlwcubm - pgbxfdermt) View more	-	09 May 2018
				Placebo (Placebo)	nfzsqtqril(oyhvosrggj) = ytotjijxnl nvwxhlnrzi (uzxipreshi, bobnjkalao - svemmkejby) View more
NCT00609739 (CTgov)	Phase 1/2	Juvenile Myelomonocytic Leukemia	1	umbilical cord blood transplantation+methylprednisolone+Cis-Retinoic acid+cyclosporine+Filgrastim+mitoxantrone hydrochloride+methotrexate+Cytarabine	(yunbiqltom) = poqmogqnok jtvyrhshhr (rfdljyllfu, ijmiggynta - brbfdovcbn) View more	-	02 Mar 2012
NCT00154284 (CERTES02, CTgov)	Phase 3	Renal transplant rejection	114	Steroid+Cyclosporine (Neoral)+Basiliximab (Simulect)+Everolimus (Certican) (Everolimus (Certican) With Cyclosporine (Neoral) Continuation)	ezqrfwmhhq(miaaxbzgdx) = sowgbvtjsx dedtkttqqe (yqhltxjfsa, anfxblmevn - dqkisekqba) View more	-	11 Mar 2011
				Steroid+Cyclosporine (Neoral)+Basiliximab (Simulect)+Everolimus (Certican) (Everolimus (Certican) With Cyclosporine (Neoral) Withdrawal)	ezqrfwmhhq(miaaxbzgdx) = hcxoeogrky dedtkttqqe (yqhltxjfsa, imadjrfirg - cwzglsoasp) View more
NCT00419926 (CTgov)	Phase 4	-	313	Cyclosporine (Neoral)+Prednisone+Enteric-coated mycophenolate sodium (Myfortic) (Intensified Mycophenolate Sodium (Myfortic) Dosing Regimen)	qmlhajdfqv(aslqfyeula) = wsdcbyvxch ijyqejqnop (piudzuwgfk, ogjzqmgcrd - gznmgfrnjk) View more	-	11 Jan 2011
				Cyclosporine (Neoral)+Prednisone+Enteric-coated mycophenolate sodium (Myfortic) (Standard Mycophenolate Sodium (Myfortic) Dosing Regimen)	qmlhajdfqv(aslqfyeula) = vqvwffzbgy ijyqejqnop (piudzuwgfk, ytpmsigalz - liqydnbfwk) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data